Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | ACACA | Q13085 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391974 | 0.92 | ACACB (0.74) | ACACBCYP2C9ACACAMAPK1ALDH1A1 | |
| SCHEMBL4391971 | 0.92 | ACACB (0.74) | ACACBCYP2C9ACACAMAPK1ALDH1A1 | |
| SCHEMBL4393444 | 0.91 | ACACB (0.62) | ACACBCYP2C9ACACATP53MAPK1 | |
| SCHEMBL4392944 | 0.91 | ACACB (0.62) | ACACBCYP2C9ACACATP53MAPK1 | |
| SCHEMBL4388602 | 0.90 | ACACB (0.76) | ACACBCYP2C9ACACAALDH1A1KDM4E | |
| SCHEMBL4388595 | 0.90 | ACACB (0.76) | ACACBCYP2C9ACACAALDH1A1KDM4E | |
| SCHEMBL13590604 | 0.87 | ACACB (0.86) | ACACBCYP2C9ACACATP53 | |
| SCHEMBL4393431 | 0.87 | CYP3A4 (0.62) | ACACBCYP2C9ACACAALDH1A1KDM4E | |
| SCHEMBL4391848 | 0.87 | CYP3A4 (0.62) | ACACBCYP2C9ACACAALDH1A1KDM4E | |
| SCHEMBL4390184 | 0.85 | ACACB (0.69) | ACACBCYP2C9ACACATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | ACACB 2/4885CYP2C9 915/4885ACACA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.